Acquired haemophilia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:28:51 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Acquired haemophilia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effectiveness of SerpinPC for Patients with Hemophilia B with Inhibitors https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-serpinpc-for-patients-with-hemophilia-b-with-inhibitors/ Wed, 29 Apr 2026 14:23:39 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-serpinpc-for-patients-with-hemophilia-b-with-inhibitors/ This clinical trial is focused on studying a condition known as Hemophilia B, which is a genetic disorder that affects the blood’s ability to clot properly. People with this condition can experience excessive bleeding even from minor injuries. The study is testing a new treatment called SerpinPC, which is a modified form of a protein known as human alpha-1 proteinase inhibitor. This treatment is given as a solution for injection under the skin.

The purpose of the study is to evaluate how effective and safe SerpinPC is for people with Hemophilia B who have developed inhibitors. Inhibitors are antibodies that can make standard treatments less effective. Participants in the study will receive regular injections of SerpinPC and will be monitored over a period of time to see how well the treatment works in reducing bleeding episodes. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects.

The study will last for a total of 48 weeks, during which participants will be closely observed for any changes in their condition and any side effects they might experience. The main focus will be on the number of bleeding episodes that require treatment, as well as the overall health and quality of life of the participants. This trial aims to provide valuable information on whether SerpinPC can be a beneficial treatment option for those living with Hemophilia B with inhibitors.

]]>